Zhongzhi Pharmaceutical Holdings (HKG:3737) plans to unwind its contractual arrangements with Zhongshan Zhongzhi Chinese Medicine Herb in Pieces as it can now directly hold equity interest in the latter, a Friday Hong Kong bourse filing said.
Zhongzhi Chinese Medicine Herb in Pieces is mainly engaged in the production of traditional and modern decoction pieces in China and is a major Chinese operating subsidiary of the group.
The company was not allowed to hold a direct interest in Zhongzhi Chinese Medicine Herb in Pieces due to the restrictions placed by the Foreign Investment Catalogue and had hence entered into contractual agreements to take management of and economic benefits from it.
As the said restrictions are now lifted in the Catalogue of Restricted Foreign Investment Industries (2024 version) issued by the National Development and Reform Commission on Sept. 8, the company now intends to hold equity interest in the Zhongzhi Chinese Medicine Herb in Pieces.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.